Presented at ESMO: the POTOMAC study on immunotherapy in non-muscle-invasive bladder cancer
Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Lancet in conversation with
Can semaglutide be used to treat alcohol use disorder?
Louise Chappell and Na’ama Carlin on Personal Cancer Stories
Susannah Stanway on the London Global Cancer Week
Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Human Health
Get summaries like this every morning.
Free AI-powered recaps of The Lancet in conversation with and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.